Marketing-authorisation holder · United States

Spectrum Pharms

United States2 medicines1 country

2 medicines in 1 country, as authorisation holder.

Medicines

Every medicine in the registers under its name, current ones first.

2 medicines

Medicine	Substance	Country	Status	Authorised
ROLVEDON13.2mg/0.6ml · Injectable	Eflapegrastim	United States	Marketed	2022
ZEVALIN3.2mg/2ml · Injectable	Ibritumomab tiuxetan (90y)	United States	Marketed	2002

Where it holds or makes medicines, with how many are current.

Country	Medicines	Current	Past	Companies
United States	2	2	0	Companies All medicines

The active substances in most of its medicines.

One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.

Marketing-authorisation holder · United States

United States2 medicines1 country

2 medicines in 1 country, as authorisation holder.

Every medicine in the registers under its name, current ones first.

2 medicines

Medicine	Substance	Country	Status	Authorised
ROLVEDON13.2mg/0.6ml · Injectable	Eflapegrastim	United States	Marketed	2022
ZEVALIN3.2mg/2ml · Injectable	Ibritumomab tiuxetan (90y)	United States	Marketed	2002

Where it holds or makes medicines, with how many are current.

Country	Medicines	Current	Past	Companies
United States	2	2	0	Companies All medicines

The active substances in most of its medicines.

One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.

How the registers spell it, normalised: legal forms, accents and capitals removed.

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Report an error or request removalCorrections from the company itself are welcome.

Ranked by their number of medicines.